Diabetes and hepatocellular carcinoma risks in patients with nonalcoholic steatohepatitis related cirrhosis
Hepatocellular carcinoma (HCC) oncogenesis in the absence of alcoholic liver disease and chronic viral hepatitis has aroused growing clinical concern in clinical practice. In the era of remarkable advances of viral hepatitis treatment, nonalcoholic steatohepatitis (NASH) has become an emerging cause of HCC (1,2). Diabetes is a major risk factor of NASH and nonalcoholic fatty liver disease (3). With the increasing burden of diabetes globally, diabetes has also been recognized for contributing to cirrhosis, HCC development, and deaths from HCC (4-6). Nonetheless, the role of diabetes in the progression of NASH-related cirrhosis to HCC is unclear.